Kornimate/medical-research-clean huggingface dataset:
docetaxel combined with estramustine in treating women with metastatic breast cancer

Conditions: Breast Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of docetaxel combined with estramustine in treating women with metastatic breast cancer.

objectives: i. determine the response rate, duration of response, duration of survival, and quality of life effects of docetaxel and estramustine combination in women with metastatic breast cancer. outline: patients receive estramustine 3 times a day for 3 days. docetaxel begins on day 3 after the a.m. dose of estramustine and is given as a 1 hour infusion intravenously. courses repeat every 21 days. if disease responds or is stable, treatment continues at the highest tolerance percentage of prescribed dose until appearance of disease progression. if complete response is documented, an additional 2 courses are given. patients should receive a minimum of 2 courses unless rapid progression or unacceptable toxicity occur. patients are followed monthly. projected accrual: approximately 40 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically confirmed metastatic breast cancer measurable or evaluable disease must be ineligible for other high priority national or institutional study no visible metastases on brain ct or mri (unless single lesion amenable to surgical resection) hormone receptor status: not specified patient characteristics: age: over 18 sex: female menopausal status: not specified performance status: ecog 0-2 life expectancy: more than 2 months hematopoietic: wbc greater than 3,000/mm3 platelet count greater than 100,000/mm3 no prior clotting disorder unless therapeutically anticoagulated hepatic: bilirubin less than the upper limit of normal sgot or sgpt less than 1.5 times normal renal: bun less than 1.5 times normal creatinine less than 1.5 times normal cardiovascular: no prior thromboembolism unless therapeutically anticoagulated other: no symptomatic ascites, pleural effusion or peripheral edema no serious medical or psychiatric illness no prior malignancy other than curatively treated carcinoma in situ of the cervix or skin cancer prior concurrent therapy: biologic therapy: not specified chemotherapy: at least 4 weeks since prior chemotherapy (2 weeks if weekly regimen) any number of prior chemotherapy regimens allowed endocrine therapy: any number of prior hormonal therapy regimens allowed radiotherapy: at least 4 weeks since prior radiotherapy surgery: at least 1 week since prior surgery

Keywords: stage iv breast cancer recurrent breast cancer
effects of tpr and z techniques on pain and drug leakage in intramuscular injections

Conditions: Muscle Pain; Injection Site Pain

Summary: this randomized, triple-blind clinical trial compares the effectiveness of z-track and tpr (traction-pressure-release) techniques in reducing pain and medication leakage during ventrogluteal intramuscular injections. pain is measured using vas, and leakage is assessed with a millimeter scale. the study aims to identify a more efficient, less painful injection method.

introduction: intramuscular (im) injections are widely used for delivering medications due to their high bioavailability and quick absorption. however, they can cause significant local complications, especially pain, which may affect patient compliance. various non-pharmacological techniques have been developed to reduce injection pain, including the z-track method and the more recent tpr (traction-pressure-release) technique, based on the gate control theory of pain. while both aim to minimize pain, tpr has shown promise but lacks research regarding its effect on drug leakage. objective: the study aims to compare the effectiveness of tpr and z-track techniques in reducing pain and drug leakage during im injections in the ventrogluteal site. method: this study is a triple-blind, randomized, two-group clinical trial with a parallel design. a total of 76 patients aged 16-40, prescribed with intramuscular diclofenac sodium, will be recruited. each participant will receive both techniques-tpr and z-track-in randomly assigned ventrogluteal muscles. pain intensity will be measured using a visual analog scale (vas), and drug leakage will be assessed using millimetric paper and a ruler. all injections will be administered by the same nurse, and evaluation will be performed by blinded assessors. conclusion: this research seeks to provide evidence on the efficacy of the tpr technique as a potentially time- and cost-effective alternative to z-track, particularly in minimizing injection-related pain and leakage, thereby improving patient comfort and treatment adherence.

Eligibility criteria:
inclusion criteria: * aged 16-40 * prescribed diclofenac sodium * no communication impairments * healthy ventrogluteal muscles without sensory issues exclusion criteria: * wounds, redness, bruising, tenderness, or stiffness at the injection site * injection in the past 2 weeks * neuropathy or other medical conditions * bmi below 15 or above 35

Keywords: intramuscular injection drug leakage l pain z-track tpr techniques
effectiveness of topical application of olive oil in preventing pressure injuries

Conditions: Disability Physical

Summary: pressure injuries (pis) pose significant public health concerns, particularly for hospitalized patients with limited mobility. they are one of the five most common causes of harm in healthcare settings, with a global prevalence ranging from 0% to 72.5%. hospitalized patients face a higher risk of developing pis compared to those in community settings, with older adults (over 65 years) being particularly vulnerable. meta-analysis reveals a global prevalence of pis at 14.8%, varying significantly across care settings. for instance, in acute care environments, the prevalence ranges from 6% to 18%, highlighting the need for improved preventive measures. a study in the uae demonstrated that implementing a new intervention protocol reduced the prevalence of pis from 2% in 2013 to 1.8% in 2018, underscoring that prevention is less costly than treatment. furthermore, research indicates that maintaining skin integrity is crucial in preventing pis, with the agency for healthcare research and quality emphasizing the use of "care bundles" that include comprehensive skin assessments. topical emollients and products containing hyper-oxygenated fatty acids (hofas) are recommended for enhancing skin hydration and reducing pi risk. evidence from studies in gulf countries shows the effectiveness of olive oil in preventing and treating pis. despite existing interventions, recent data from the hospital conducting this study revealed a rising incidence of pis, from 40 cases in 2020 to 55 cases in 2021. this research aims to evaluate the effectiveness of applying extra virgin olive oil topically, alongside standard preventive measures, to reduce the risk of pis in mobility-compromised patients.


Eligibility criteria:
inclusion criteria: - mobility-limited stroke, spinal cord injuries, fractures, multiple sclerosis exclusion criteria: unwilling to participate,

Keywords: olive oil, pressure injury, mobility limitations, united arab emirates
a study of anti-pd-l1 antibody in neoadjuvant chemotherapy of esophageal squamous cell carcinoma.

Conditions: Esophageal Cancer

Summary: this is a randomized, double-blind, placebo-controlled ib/ⅱ clinical study to evaluate the safety and effect of anti-pd-l1 antibody (zkab001) in neoadjuvant chemotherapy of esophageal squamous carcinoma in combination with alb-paclitaxel and cisplatin. the immunotherapy will be given before and after the operation every three weeks.


Eligibility criteria:
key inclusion criteria: 1. aged 18 to 75 years old of either gender; 2. a histopathological diagnosis of esophageal squamous cell carcinoma with a clinical stage of t2n+m0 or t3-4an+/-m0 according to the 8th edition of the uicc staging system; 3. ecog score 0-1; 4. estimated life expectancy \>3 months; 5. bmi ≥18.5kg/m2 or pg-sga score a/b; 6. the function of important organs meets the following requirements: 1. white blood cell count (wbc) ≥ 3.0×109/l, absolute neutrophil count (anc) ≥ 1.5×109/l, platelets ≥ 100×109/l, hemoglobin ≥ 90g/l; 2. alt, ast and akp ≤ 2.5×uln; 3. serum albumin ≥ 30g/l; 4. total bilirubin ≤ 1.5×uln; 5. serum creatinine ≤ 1.0×uln, creatinine clearance rate ≥60 ml/min; 6. inr ≤ 1.5, pt≤ 1.5×uln; 7. cardiac function: ≤i, pulmonary function: fev1 \>1.2l, fev1% \>40%, liver function: child-pugh 5-6; 8. serum hcg negative in premenopausal women ; 9. ability to understand the study and sign informed consent. key exclusion criteria: 1. cervical esophageal carcinoma; 2. patients who have been treated previously with anti-tumor therapy (including chemotherapy, radiotherapy, surgery, immunotherapy, etc.); 3. known or suspected allergy or hypersensitivity to monoclonal antibodies, any ingredients of anti-pd-l1 antibody and chemotherapeutic drugs; 4. active autoimmune diseases; 5. a history of allogeneic stem cell transplantation and organ transplantation; 6. a history of interstitial lung disease or non-infectious pneumonia; 7. patients who cannot tolerate chemotherapy or surgery due to severe cardiac, lung, liver or kidney dysfunction, or hematopoietic disease or cachexia; 8. a history of immunodeficiency (including a positive hiv test result), or other acquired or congenital immunodeficiency diseases; 9. presence of active hepatitis b (hbv dna ≥ 200 iu/ml or 103 copies/ml), hepatitis c (positive for hepatitis c antibody, and hcv-rna levels higher than the lower limit of the assay); 10. a history of active pulmonary tuberculosis infection within 1 year or a history of active pulmonary tuberculosis infection more than 1 year ago but without formal anti-tuberculosis treatment; 11. a history of malignancies other than esophageal cancer before enrollment, excluding non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer; 12. lymph node metastasis in neck, supraclavicular, abdominal cavity, retroperitoneum and pelvic cavity (except paracardial and left gastric lymph nodes).

Keywords: esophageal cancer immunotherapy
acne treatment with active oplon's patches - 15-18 years old

Conditions: Acne Vulgaris

Summary: the purpose of this study was to demonstrate the effect of short treatment with active oplon patches on acne.

patients with acne vulgaris were treated overnight with active patches. effect is observed at the end of the treatment and 24 hours later.

Eligibility criteria:
inclusion criteria: * acne vulgaris * over 15 years * signing informed consent exclusion criteria: * active treatment of acne * change in hormonal therapy * antibiotic treatment in a week prior to the experiment * sensitive skin * pregnancy
the everolimus-transplant exit strategy trial (e-test)

Conditions: Kidney Failure, Chronic

Summary: the purpose of this study is to test the safety and effectiveness of everolimus (zortress®) in preventing antibody formation in patients with chronic failing kidney transplants. everolimus (zortress®) is approved by the u.s. food and drug administration for the prevention of rejection in kidney transplant. the primary objective for the study is to determine whether conversion of patients with chronic renal graft failure approaching dialysis to an everolimus-based regimen will prevent allosensitization. the secondary objective will be to determine whether conversion of patients with chronic renal graft failure to everolimus (elimination of calcineurin inhibitor) will delay the onset of dialysis.


Eligibility criteria:
inclusion criteria: * recipient of deceased or living donor kidney transplant * age 18-75 years (inclusive) * male or female * renal allograft dysfunction/deterioration evidenced by glomerular filtration rate (gfr) less than or equal to 35 * grade 2 or 3 interstitial fibrosis/tubular atrophy (if/ta) on renal allograft biopsy within 5 years of enrollment * willing and able to provide informed consent for study participation exclusion criteria: * prior solid organ transplant (other than kidney) * history of donor-specific antibody * history of biopsy-proven acute rejection within 1 year prior to enrollment * proteinuria greater than or equal to 1.5 gm on spot urine protein/creatinine ratio * evidence of hepatitis c virus infection (antibody positive or polymerase chain reaction(pcr) positive) * epstein barr virus (ebv) or cytomegalovirus (cmv) viremia at the time of enrollment * subjects receiving belatacept (nulojix) * pregnant or nursing (lactating) women * women of child-bearing potential (wocbp) who are unwilling or unable to use two birth-control methods throughout participation in the study

Keywords: chronic allograft failure kidney transplantation
noc2 spine registry

Conditions: Spinal Disease

Summary: the primary objective of the spine registry is to enhance the understanding of spinal disease and treatment of spinal disease with the goal of guiding treatment options.

this study will enhance the understanding of the variability, progression and treatment of spinal disease with the ultimate goal of better guiding and assessing therapeutic intervention. researchers will collect complications and safety following cervical and lumbar surgeries to determine best options for patients. prospective reports will be collected on patients undergoing lumbar or cervical spinal surgery. patients will be enrolled in registry after signing informed consent. data will be collected at various time points. the registry will serve as a database of cervical and lumbar surgeries in which retrospective analysis and exploratory analysis of specific research questions can be answered.

Eligibility criteria:
inclusion criteria: * patients undergoing lumbar or cervical surgery * understand and sign informed consent exclusion criteria: * there are no specific exclusion criteria

Keywords: cervical lumbar spine spinal disease
lymphedema prevention in breast cancer

Conditions: Breast Cancer; Lymphedema

Summary: objective: to find out the effectiveness of early application of manual lymph drainage in the prevention of upper limb lymphedema after breast surgery and axillary lymphadenectomy in women with breast cancer. design: randomized, controlled and single blinded clinical trial. five years duration. patients were randomly assigned to one of these groups: experimental group: manual lymph drainage + training in means of prevention; control group: just training in means of prevention. in both groups several physical therapy assessments were undertaken: 1st before surgery; 2nd 3 month after surgery; 4th, 5th, 6th, 7th, 8th and 9th after 6, 12, 24, 36, 48 and 60 months. subjects: women with breast cancer treated with breast surgery including axillary lymphadenectomy in provincial hospital of toledo, provided that there is no contraindication for manual lymph drainage, and after reading, understanding and freely signing an informed consent form. sample size: a total of 150 subjects were included in the study (57 subjects in experimental group and 93 in control group), assuming a 20% of drop-outs and at least 25% reduction, with a statistical power of 75%. data analysis: to find out the effectiveness of intervention the investigators will compare the rate of lymphedema in both groups by means of a logistic regression analysis, in which the main factor is the intervention group. other factors aimed to control the effect of the intervention will also be included. in order to compare the rate of appearance of lymphedema in both groups, a survival analysis will also be included.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of breast cancer. * undergoing unilateral surgery with axillary lymph-node dissection. exclusion criteria: * bilateral breast cancer. * systemic disease. * locoregional recurrence. * any contraindication to physical therapy.

Keywords: lymphedema prevention
method of fish oil administration on patient compliance

Conditions: Adverse Effects

Summary: many patients complain of fishy breath, upset stomach, or heartburn when taking the recommended amount of fish oil. a common recommendation made by pharmacists is to freeze the fish oil capsules to help decrease adverse gastrointestinal effects. compliance with over-the-counter (otc) fish oil is a concern considering the high number of capsules taken daily. the hypothesis of this study is that taking fish oil with milk will help lead to better patient compliance with no difference in adverse effects versus other administration methods.

fish oil has many proposed health benefits such as lowering triglycerides, decreasing inflammation, and reducing risk factors for cardiovascular disease. in order to take the recommended daily dose for hypertriglyceridemia using an otc fish oil supplement, the daily recommended dose is at least 2 grams (2 capsules) three times a day. the american heart association recommends 2-4 grams of omega-3 fatty acid a day to aid in triglyceride reduction. fish oil is known to cause gi-related adverse effects. although reported to help, freezing fish oil capsules is inconvenient requiring access to a freezer three times a day. currently there is a lack of literature to specify the best administration technique or patient compliance data for otc fish oil supplements. the purpose of this study is to determine an ideal method of taking fish oil. this study will include up to 60 patients that are between the ages of 18-65 years who would be considered generally healthy. patients will be recruited via e-mails sent to faculty and students of the school of pharmacy, via flyers in walgreen's stores, and through word of mouth. the patients will be randomly assigned to one of four treatment groups. each treatment group will be given 180 capsules and instructed to take two capsules three times a day for thirty days with either food, no food, milk, or frozen. at the end of thirty days, the patient will return the bottle with any remaining pills to the investigator and take a survey. the investigators will assess compliance via pill count.

Eligibility criteria:
inclusion criteria: * patients 18-65 years of age * minimal medication usage and controlled chronic health conditions exclusion criteria: * patients with significant renal, hepatic, autoimmune or gastrointestinal tract disease * patients with uncontrolled chronic health conditions (e.g., diabetes, high blood pressure, high cholesterol or hypothyroidism) * receiving prescription anti-coagulation, prescription anti-platelet, prescription anti-inflammatory drugs, biologics, chronic steroids, chemotherapy, or otherwise excessive medication regimens * pregnant/nursing women, \<18 years of age, prisoners, or the mentally ill

Keywords: hyperlipidemias dyslipidemias fatty acids, omega-3 fish oils
effect of a physical activity and nutrition education intervention on obesity prevalence in schoolchildren

Conditions: Childhood Obesity

Summary: childhood obesity is a major global public health problem. several strategies have been implemented to reduce the high prevalence, the most cost-effective of which were those that focused on the school environment. although there is vast research that focus on interventions that address obesity through interventions to improve schoolchildren diets and physical activity level in many countries of the latin american region, there is lack of evidence of the effectiveness of multicomponent interventions that aim to reduce the prevalence of obesity among schoolchildren in the paraguayan context.

nutritional education and physical activity. interventions that promote healthy eating and lifelong physical activity in schoolchildren through school programs aim to equip children with knowledge, attitudes and behavioral skills to help them establish and maintain a healthy lifestyle. poor diet quality has been identified as one of the main factors contributing to the obesity epidemic. research has shown that a diet that includes the recommended servings of fruits and vegetables (vf) reduces morbidity and mortality from non-communicable diseases (ncds) and has also been linked to a lower risk of adiposity. therefore, the need to promote the consumption of vf from an early age through effective programs. the interventions in physical activity have shown effective results in the decrease of bmi, the thickness of the skin folds and the percentage of fat mass in school-age children. taking into account that currently the schoolchildren have decreased the amount of time dedicated to games, sports or other types of movement and the hours of sedentary life and in front of the screens (computers, tablets, television, mobile phones, others) have increased. it is necessary to promote the performance of physical activity in the school environment through permanent programs that contribute to improving the physical condition of children, complying with daily recommendations.

Eligibility criteria:
inclusion criteria: * being public or private schools of the 22 districts of caaguazú department * having a minimum of 100 students in each of the three grades of second level of basic school education during 2017 school year * having physical education teachers exclusion criteria: * schools that had only one school shift * schools that expressed their refusal to participate

Keywords: childhood obesity, nutrition education, physical activity intervention, schools